At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SRXH Srx Global Inc
Pre-Mkt 10-30 05:48:18 EDT
1.01
-0.03
-2.88%
盘前1.02
+0.01+0.99%
04:46 EDT
High1.07Low1.00Vol287.32K
Open1.04D1 Closing1.04Amplitude6.73%
Mkt Cap20.47MTradable Cap14.29MTotal Shares20.27M
T/O296.07KT/O Rate2.03%Tradable Shares14.15M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

SRX Global Announces UC Davis as New Site for CERo’s Phase 1 CER-1236 Trial
Reuters  ·  10-26
SRX Global Announces UC Davis as New Site for CERo’s Phase 1 CER-1236 Trial
Srx Global Announces Activation of the University of California, Davis as a Clinical Trial Site for Cero Therapeutics’ Ongoing Phase 1 Certain-T Trial of Cer-1236 in Hematologic Malignancies
THOMSON REUTERS  ·  10-26
Srx Global Announces Activation of the University of California, Davis as a Clinical Trial Site for Cero Therapeutics’ Ongoing Phase 1 Certain-T Trial of Cer-1236 in Hematologic Malignancies
SRX Global Forms Joint Venture with 5T Trading to Launch Multi-Strategy Trading Platform Fund
Reuters  ·  10-08
SRX Global Forms Joint Venture with 5T Trading to Launch Multi-Strategy Trading Platform Fund
Srx Global Commits $2.5 Million to Launch Multi-Strategy Trading Platform in Partnership with 5T Trading, Powered by the Emjx Platform
THOMSON REUTERS  ·  10-08
Srx Global Commits $2.5 Million to Launch Multi-Strategy Trading Platform in Partnership with 5T Trading, Powered by the Emjx Platform
Srx Global - Acquisition Expected to Accelerate Development of Cer-1236 for Hematologic Malignancies
THOMSON REUTERS  ·  10-08
Srx Global - Acquisition Expected to Accelerate Development of Cer-1236 for Hematologic Malignancies
Srx Global - Cero 1236, Spv to Raise Capital Without Diluting Srx Global Shareholders
THOMSON REUTERS  ·  10-08
Srx Global - Cero 1236, Spv to Raise Capital Without Diluting Srx Global Shareholders
Srx Global - Andrew Kucharchuk Expected to Serve as President of Cero Therapeutics
THOMSON REUTERS  ·  10-08
Srx Global - Andrew Kucharchuk Expected to Serve as President of Cero Therapeutics
Srx Global and Cero 1236, a Wholly-Owned Spv, Enter into Definitive Agreement to Acquire Cero Therapeutics, an Innovative Cellular Immunotherapy Company Developing Cer 1236 for Hematologic Malignancies
THOMSON REUTERS  ·  10-08
Srx Global and Cero 1236, a Wholly-Owned Spv, Enter into Definitive Agreement to Acquire Cero Therapeutics, an Innovative Cellular Immunotherapy Company Developing Cer 1236 for Hematologic Malignancies
Srx Global - Enters Stock Purchase Agreement with Cero Therapeutics Holdings on Oct 6, 2026 - SEC Filing
THOMSON REUTERS  ·  10-07
Srx Global - Enters Stock Purchase Agreement with Cero Therapeutics Holdings on Oct 6, 2026 - SEC Filing
Srx Global - to Buy All Outstanding Stock of Cero Therapeutics, - SEC Filing
THOMSON REUTERS  ·  10-07
Srx Global - to Buy All Outstanding Stock of Cero Therapeutics, - SEC Filing
SRX Global to Acquire CERo Therapeutics Unit from CERo Therapeutics Holdings
Reuters  ·  10-07
SRX Global to Acquire CERo Therapeutics Unit from CERo Therapeutics Holdings
Srx Global Commits $1.5 Mln to Launch Family of AI-Powered Etfs Through Its Emjx Platform
THOMSON REUTERS  ·  10-07
Srx Global Commits $1.5 Mln to Launch Family of AI-Powered Etfs Through Its Emjx Platform
SRX Global Commits $1.5 Million to Launch AI-Powered ETF Family Via EMJX Platform
Reuters  ·  10-07
SRX Global Commits $1.5 Million to Launch AI-Powered ETF Family Via EMJX Platform
SRX Global says adds investment in Onconetix
TIPRANKS  ·  09-25
SRX Global says adds investment in Onconetix
SRX Global Adds Minority Equity Stake in Onconetix
Reuters  ·  09-25
SRX Global Adds Minority Equity Stake in Onconetix
Srx Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: Onco)
THOMSON REUTERS  ·  09-25
Srx Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: Onco)
SRX Global CEO Cunningham, EMJX Platform Head Jackson to Present at Webull Fintech Investor Webinar
Reuters  ·  09-24
SRX Global CEO Cunningham, EMJX Platform Head Jackson to Present at Webull Fintech Investor Webinar
SRX Global Sells 3,579 Series C Preferred Shares in $2.83 Million Private Placement
Reuters  ·  09-10
SRX Global Sells 3,579 Series C Preferred Shares in $2.83 Million Private Placement
SRX Global Says ARMR-100 Fentanyl Vaccine Generates Immune Response in Phase 1/2 Trial
Reuters  ·  09-03
SRX Global Says ARMR-100 Fentanyl Vaccine Generates Immune Response in Phase 1/2 Trial
Srx Global Provides Shareholder Update on Portfolio Company, Armr Sciences, a Clinical-Stage Biodefense Company
THOMSON REUTERS  ·  09-03
Srx Global Provides Shareholder Update on Portfolio Company, Armr Sciences, a Clinical-Stage Biodefense Company

Introduction

Company Name.
Srx Global Inc
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
Better Choice Company Inc. operates as an animal health and wellness company. Its products portfolio includes naturally formulated kibble and canned dog and cat foods, freeze-dried raw dog foods and treats, vegan dog foods and treats, oral care products and supplements, as well as toppers, dental products, chews, and grooming products. The company sells its products under Halo Holistic and Halo Elevate brands. Better Choice Company Inc. primarily sells its products through its online portals, as well as through online retailers and pet specialty stores. It has operations in the United States, Canada, China, and Asia. The company was formerly known as Sports Endurance, Inc. and changed its name to Better Choice Company Inc. in March 2019. Better Choice Company Inc. was founded in 1986 and is based in Tampa, Florida.
Issue price:
--